|
|
| Product Name: | SB1317 | | Synonyms: | TG-02/SB-1317;14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene;SB1317, >=98%;SB1317(TG-02) hydrochloride;CS-915;TG02; SB 1317; TG 02; SB-1317; TG-02;TG02;TG-02;20-Oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-methyl- | | CAS: | 937270-47-8 | | MF: | C23H24N4O | | MW: | 372.46 | | EINECS: | | | Product Categories: | | | Mol File: | 937270-47-8.mol |  |
| | SB1317 Chemical Properties |
| Boiling point | 575.5±60.0 °C(Predicted) | | density | 1.16±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; ≥44.87 mg/mL in DMSO; ≥3.98 mg/mL in EtOH with gentle warming and ultrasonic | | form | solid | | pka | 8.03±0.20(Predicted) |
| | SB1317 Usage And Synthesis |
| Uses | TG 02 is a cyclin dependent kinase inhibitors (CDK inhibitors) for the treatment of chronic lymphocytic leukemia. |
| | SB1317 Preparation Products And Raw materials |
|